The global pharmaceutical industry experienced a 14% decline in the number of microbiome-related patent applications in Q2 2024 compared with the previous quarter. The total number of microbiome-related grants dropped by 10% in Q2 2024, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q2 2024 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.
Notably, the number of microbiome-related patent applications in the pharmaceutical industry was 230 in Q2 2024, versus 266 in the prior quarter.
The top five companies accounted for 12% of patenting activity
Analysis of patenting activity by companies shows that DSM-Firmenich filed the most microbiome patents within the pharmaceutical industry in Q2 2024. The company filed 11 microbiome-related patents in the quarter, compared with 3 in the previous quarter. It was followed by AOBiome with 5 microbiome patent filings, University of California (4 filings), and French National Institute of Health and Medical Research (4 filings) in Q2 2024.
Patenting activity was driven by the US with a 46% share of total patent filings
The largest share of microbiome related patent filings in the pharmaceutical industry in Q2 2024 was in the US with 46%, followed by Australia (12%) and China (4%). The share represented by the US was 7% higher than the 39% share it accounted for in Q1 2024.
For further understanding of GlobalData's Pharma: Patents Trends Q2 2024, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.